Trastuzumab biosimilar (Synthon)

曲妥珠单抗生物类似药 (Synthon)

Report date: 2022/06/22 17:38:01

Base Information

Drug NameTrastuzumab biosimilar (Synthon)
Drug Alias NameTrastuzumabum (Allergan/Amgen)曲司珠单抗生物仿制药 (Allergan/Amgen)曲妥珠单抗生物仿制药 (Allergan/Amgen)Trastuzumab-annstrastuzumab beta +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[30] 
Global Approved IndicationsStomach NeoplasmsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2018/05/16
Country/TerritoryBulgariaCanadaUnited States +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSynthon Bv
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Europe BvNational Cancer InstituteAmgen Inc +[5] 
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[30] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC03
Related LinksN/A